Influence of the Tr-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes

被引：26

作者：

Hanif, Muhammad ^{[1
,2
,3
]}

Meier, Samuel M. ^{[2
,4
]}

Nazarov, Alexey A. ^{[2
,5
,6
]}

Risse, Julie ^{[6
]}

Legin, Anton ^{[2
]}

Casini, Angela ^{[7
]}

Jakupec, Michael A. ^{[2
,4
]}

Keppler, Bernhard K. ^{[2
,4
]}

Hartinger, Christian G. ^{[1
,2
,4
]}

机构：

[1] Univ Auckland, Sch Chem Sci, Private Bag 92019, Auckland 1142, New Zealand

[2] Univ Vienna, Inst Inorgan Chem, Vienna, Austria

[3] COMSATS Inst Informat Technol, Dept Chem, Abbottabad, Pakistan

[4] Univ Vienna, Res Platform Translat Canc Therapy Res, Vienna, Austria

[5] Moscow MV Lomonosov State Univ, Dept Chem, Moscow, Russia

[6] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, Lausanne, Switzerland

[7] Univ Groningen, Res Inst Pharm, Pharmacokinet Toxicol & Targeting, Groningen, Netherlands

来源：

FRONTIERS IN CHEMISTRY | 2013年 / 1卷

基金：

俄罗斯基础研究基金会; 奥地利科学基金会;

关键词：

anticancer activity; bioorganometallic chemistry; carbohydrates; phosphorus ligands; ruthenium arene compounds;

D O I：

10.3389/fchem.2013.00027

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The synthesis and in vitro cytotoxicity of a series of Rull(arene) complexes with carbohydrate-derived phosphite ligands and various arene co-ligands is described. The arene ligand has a strong influence on the in vitro anticancer activity of this series of compounds, which correlates fairly well with cellular accumulation. The most lipophilic compound bearing a biphenyl moiety and a cyclohexylidene-protected carbohydrate is the most cytotoxic with unprecedented IC50 values for the compound class in three human cancer cell lines. This compound shows reactivity to the DNA model nucleobase 9-ethylguanine, but does not alter the secondary structure of plasmid DNA, indicating that other biological targets are responsible for its cytotoxic effect.

引用

页码：1 / 7

页数：7

共 31 条

[1] In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].

Aird, RE ;

Cummings, J ;

Ritchie, AA ;

Muir, M ;

Morris, RE ;

Chen, H ;

Sadler, PJ ;

Jodrell, DI .

BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657

[2] (ETA-6-HEXAMETHYLBENZENE)RUTHENIUM COMPLEXES [J].

BENNETT, MA ;

HUANG, TN ;

MATHESON, TW ;

SMITH, AK .

INORGANIC SYNTHESES, 1982, 21 :74-78

[3] In Vitro Anticancer Activity and Biologically Relevant Metabolization of Organometallic Ruthenium Complexes with Carbohydrate-Based Ligands [J].

Berger, Isabella ;

Hanif, Muhammad ;

Nazarov, Alexey A. ;

Hartinger, Christian G. ;

John, Roland O. ;

Kuznetsov, Maxim L. ;

Groessl, Michael ;

Schmitt, Frederic ;

Zava, Olivier ;

Biba, Florian ;

Arion, Vladimir B. ;

Galanski, Markus ;

Jakupec, Michael A. ;

Juillerat-Jeanneret, Lucienne ;

Dyson, Paul J. ;

Keppler, Bernhard K. .

CHEMISTRY-A EUROPEAN JOURNAL, 2008, 14 (29) :9046-9057

[4] Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium (II)-Arene Compounds [J].

Casini, Angela ;

Gabbiani, Chiara ;

Sorrentino, Francesca ;

Rigobello, Maria Pia ;

Bindoli, Alberto ;

Geldbach, Tifimann J. ;

Marrone, Alessandro ;

Re, Nazzareno ;

Hartinger, Christian G. ;

Dyson, Paul J. ;

Messori, Luigi .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (21) :6773-6781

[5] Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: Novel recognition mechanisms [J].

Chen, HM ;

Parkinson, JA ;

Morris, RE ;

Sadler, PJ .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (01) :173-186

[6] Systematic design of a targeted organometallic antitumor drug in pre-clinical development [J].

Dyson, Paul J. .

CHIMIA, 2007, 61 (11) :698-703

[7] Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells [J].

Egger, Alexander E. ;

Rappel, Christina ;

Jakupec, Michael A. ;

Hartinger, Christian G. ;

Heffeter, Petra ;

Keppler, Bernhard K. .

JOURNAL OF ANALYTICAL ATOMIC SPECTROMETRY, 2009, 24 (01) :51-61

[8] Cysteine proteases as targets for metal-based drugs [J].

Fricker, Simon P. .

METALLOMICS, 2010, 2 (06) :366-377

[9] Inhibitors of cathepsin B [J].

Frlan, R. ;

Gobec, S. .

CURRENT MEDICINAL CHEMISTRY, 2006, 13 (19) :2309-2327

[10] Organometallic Anticancer Compounds [J].

Gasser, Gilles ;

Ott, Ingo ;

Metzler-Nolte, Nils .

JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (01) :3-25

← 1 2 3 4 →